Anti-tumor effects of canine adipose tissue-derived mesenchymal stromal cell-based interferon-β gene therapy and cisplatin in a mouse melanoma model

Kyoung Won Seo, Hee Woo Lee, Ye In Oh, Jin Ok Ahn, Ye Rin Koh, Seung Hyun Oh, Sung Keun Kang, Hwa Young Youn

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background aims. Adipose tissue (AT)-derived mesenchymal stromal cells (MSC) (AT-MSC) represent a novel tool for delivering therapeutic genes to tumor cells. Interferon (IFN)-β is a cytokine with pleiotropic cellular functions, including anti-proliferative, immunomodulatory and anti-angiogenic activities. The purpose of this study was to engineer canine AT-MSC (cAT-MSC) producing IFN-β and to evaluate the anti-tumor effect of cAT-MSCIFN-β combined with cisplatin in mouse melanoma model. Methods. cAT-MSC engineered to express mouse IFN-β were generated using a lentiviral vector (cAT-MSCIFN-β) and the secreted IFN-β-induced inhibition of tumor cell growth and apoptosis on B16F10 cells was investigated in vitro prior to in vivo studies. Melanoma-bearing mouse was developed by injecting B16F10 cells subcutaneously into 6-week-old C57BL/6 mice. After 14 days, cisplatin (10 mg/kg) was injected intratumorally, and 3 days later the engineered cAT-MSC were injected subcutaneously every 3 days to death. Tumor volume and survival times were measured. Results. The combination treatment of cAT-MSCIFN-β with cisplatin was more effective in inhibiting the growth of melanoma and resulted in significantly extended survival time than both an unengineered cAT-MSCcisplatin combination group and a cisplatin-alone group. Interestingly, subcutaneously injected cAT-MSCIFN-β were migrated to tumor sites. Conclusions. Our data suggest that canine AT-MSC could serve as a powerful cell-based delivery vehicle for releasing therapeutic proteins to tumor lesions. Maximal anti-tumor effects were seen when this therapy was combined with a DNA-damaging chemotherapeutic agent. This study demonstrates the possible applicability of AT-MSC-mediated IFN-β in treating canine and human cancer patients.

Original languageEnglish (US)
Pages (from-to)944-955
Number of pages12
JournalCytotherapy
Volume13
Issue number8
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Mesenchymal Stromal Cells
Genetic Therapy
Interferons
Cisplatin
Canidae
Adipose Tissue
Melanoma
Neoplasms
Survival
Therapeutics
Growth
Tumor Burden
Inbred C57BL Mouse
Apoptosis
Cytokines
DNA
Genes
Proteins

Keywords

  • adipose tissue-derived mesenchymal stromal cells
  • canine
  • cell vehicle
  • interferon-β
  • melanoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Transplantation
  • Cancer Research

Cite this

Anti-tumor effects of canine adipose tissue-derived mesenchymal stromal cell-based interferon-β gene therapy and cisplatin in a mouse melanoma model. / Seo, Kyoung Won; Lee, Hee Woo; Oh, Ye In; Ahn, Jin Ok; Koh, Ye Rin; Oh, Seung Hyun; Kang, Sung Keun; Youn, Hwa Young.

In: Cytotherapy, Vol. 13, No. 8, 01.01.2011, p. 944-955.

Research output: Contribution to journalArticle

Seo, Kyoung Won ; Lee, Hee Woo ; Oh, Ye In ; Ahn, Jin Ok ; Koh, Ye Rin ; Oh, Seung Hyun ; Kang, Sung Keun ; Youn, Hwa Young. / Anti-tumor effects of canine adipose tissue-derived mesenchymal stromal cell-based interferon-β gene therapy and cisplatin in a mouse melanoma model. In: Cytotherapy. 2011 ; Vol. 13, No. 8. pp. 944-955.
@article{d821c6d214ae4cbb9af66fbcfbf25610,
title = "Anti-tumor effects of canine adipose tissue-derived mesenchymal stromal cell-based interferon-β gene therapy and cisplatin in a mouse melanoma model",
abstract = "Background aims. Adipose tissue (AT)-derived mesenchymal stromal cells (MSC) (AT-MSC) represent a novel tool for delivering therapeutic genes to tumor cells. Interferon (IFN)-β is a cytokine with pleiotropic cellular functions, including anti-proliferative, immunomodulatory and anti-angiogenic activities. The purpose of this study was to engineer canine AT-MSC (cAT-MSC) producing IFN-β and to evaluate the anti-tumor effect of cAT-MSCIFN-β combined with cisplatin in mouse melanoma model. Methods. cAT-MSC engineered to express mouse IFN-β were generated using a lentiviral vector (cAT-MSCIFN-β) and the secreted IFN-β-induced inhibition of tumor cell growth and apoptosis on B16F10 cells was investigated in vitro prior to in vivo studies. Melanoma-bearing mouse was developed by injecting B16F10 cells subcutaneously into 6-week-old C57BL/6 mice. After 14 days, cisplatin (10 mg/kg) was injected intratumorally, and 3 days later the engineered cAT-MSC were injected subcutaneously every 3 days to death. Tumor volume and survival times were measured. Results. The combination treatment of cAT-MSCIFN-β with cisplatin was more effective in inhibiting the growth of melanoma and resulted in significantly extended survival time than both an unengineered cAT-MSCcisplatin combination group and a cisplatin-alone group. Interestingly, subcutaneously injected cAT-MSCIFN-β were migrated to tumor sites. Conclusions. Our data suggest that canine AT-MSC could serve as a powerful cell-based delivery vehicle for releasing therapeutic proteins to tumor lesions. Maximal anti-tumor effects were seen when this therapy was combined with a DNA-damaging chemotherapeutic agent. This study demonstrates the possible applicability of AT-MSC-mediated IFN-β in treating canine and human cancer patients.",
keywords = "adipose tissue-derived mesenchymal stromal cells, canine, cell vehicle, interferon-β, melanoma",
author = "Seo, {Kyoung Won} and Lee, {Hee Woo} and Oh, {Ye In} and Ahn, {Jin Ok} and Koh, {Ye Rin} and Oh, {Seung Hyun} and Kang, {Sung Keun} and Youn, {Hwa Young}",
year = "2011",
month = "1",
day = "1",
doi = "10.3109/14653249.2011.584864",
language = "English (US)",
volume = "13",
pages = "944--955",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Anti-tumor effects of canine adipose tissue-derived mesenchymal stromal cell-based interferon-β gene therapy and cisplatin in a mouse melanoma model

AU - Seo, Kyoung Won

AU - Lee, Hee Woo

AU - Oh, Ye In

AU - Ahn, Jin Ok

AU - Koh, Ye Rin

AU - Oh, Seung Hyun

AU - Kang, Sung Keun

AU - Youn, Hwa Young

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Background aims. Adipose tissue (AT)-derived mesenchymal stromal cells (MSC) (AT-MSC) represent a novel tool for delivering therapeutic genes to tumor cells. Interferon (IFN)-β is a cytokine with pleiotropic cellular functions, including anti-proliferative, immunomodulatory and anti-angiogenic activities. The purpose of this study was to engineer canine AT-MSC (cAT-MSC) producing IFN-β and to evaluate the anti-tumor effect of cAT-MSCIFN-β combined with cisplatin in mouse melanoma model. Methods. cAT-MSC engineered to express mouse IFN-β were generated using a lentiviral vector (cAT-MSCIFN-β) and the secreted IFN-β-induced inhibition of tumor cell growth and apoptosis on B16F10 cells was investigated in vitro prior to in vivo studies. Melanoma-bearing mouse was developed by injecting B16F10 cells subcutaneously into 6-week-old C57BL/6 mice. After 14 days, cisplatin (10 mg/kg) was injected intratumorally, and 3 days later the engineered cAT-MSC were injected subcutaneously every 3 days to death. Tumor volume and survival times were measured. Results. The combination treatment of cAT-MSCIFN-β with cisplatin was more effective in inhibiting the growth of melanoma and resulted in significantly extended survival time than both an unengineered cAT-MSCcisplatin combination group and a cisplatin-alone group. Interestingly, subcutaneously injected cAT-MSCIFN-β were migrated to tumor sites. Conclusions. Our data suggest that canine AT-MSC could serve as a powerful cell-based delivery vehicle for releasing therapeutic proteins to tumor lesions. Maximal anti-tumor effects were seen when this therapy was combined with a DNA-damaging chemotherapeutic agent. This study demonstrates the possible applicability of AT-MSC-mediated IFN-β in treating canine and human cancer patients.

AB - Background aims. Adipose tissue (AT)-derived mesenchymal stromal cells (MSC) (AT-MSC) represent a novel tool for delivering therapeutic genes to tumor cells. Interferon (IFN)-β is a cytokine with pleiotropic cellular functions, including anti-proliferative, immunomodulatory and anti-angiogenic activities. The purpose of this study was to engineer canine AT-MSC (cAT-MSC) producing IFN-β and to evaluate the anti-tumor effect of cAT-MSCIFN-β combined with cisplatin in mouse melanoma model. Methods. cAT-MSC engineered to express mouse IFN-β were generated using a lentiviral vector (cAT-MSCIFN-β) and the secreted IFN-β-induced inhibition of tumor cell growth and apoptosis on B16F10 cells was investigated in vitro prior to in vivo studies. Melanoma-bearing mouse was developed by injecting B16F10 cells subcutaneously into 6-week-old C57BL/6 mice. After 14 days, cisplatin (10 mg/kg) was injected intratumorally, and 3 days later the engineered cAT-MSC were injected subcutaneously every 3 days to death. Tumor volume and survival times were measured. Results. The combination treatment of cAT-MSCIFN-β with cisplatin was more effective in inhibiting the growth of melanoma and resulted in significantly extended survival time than both an unengineered cAT-MSCcisplatin combination group and a cisplatin-alone group. Interestingly, subcutaneously injected cAT-MSCIFN-β were migrated to tumor sites. Conclusions. Our data suggest that canine AT-MSC could serve as a powerful cell-based delivery vehicle for releasing therapeutic proteins to tumor lesions. Maximal anti-tumor effects were seen when this therapy was combined with a DNA-damaging chemotherapeutic agent. This study demonstrates the possible applicability of AT-MSC-mediated IFN-β in treating canine and human cancer patients.

KW - adipose tissue-derived mesenchymal stromal cells

KW - canine

KW - cell vehicle

KW - interferon-β

KW - melanoma

UR - http://www.scopus.com/inward/record.url?scp=80051903684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051903684&partnerID=8YFLogxK

U2 - 10.3109/14653249.2011.584864

DO - 10.3109/14653249.2011.584864

M3 - Article

C2 - 21846298

AN - SCOPUS:80051903684

VL - 13

SP - 944

EP - 955

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 8

ER -